Dengue subunit vaccine - Merck Sharp and Dohme

Drug Profile

Dengue subunit vaccine - Merck Sharp and Dohme

Alternative Names: DEN 1 80E; Dengue subunit vaccine - Hawaii Biotech; HB6; HBV-001 D1; Tetravalent dengue vaccine - Merck Sharp & Dohme; V 180

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hawaii Biotech
  • Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
  • Class Dengue vaccines; Subunit vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Dengue

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Dengue(In volunteers) in Australia (IM, Injection)
  • 04 Dec 2015 Hawaii Biotech plans a phase I trial for Dengue in USA
  • 05 Nov 2015 Hawaii receives SBIR grant from NIH for Dengue vaccine development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top